Anti-amyloid Alzheimer's drugs show no clinically meaningful effect
medicalxpress - Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new review in the Cochrane Database of Systematic Reviews has found.
AI Summary: A major review concludes anti-amyloid Alzheimer’s medications show no clinically meaningful effect on patients’ cognition or daily function, prompting renewed debate about drug approvals, prescribing and research priorities. The analysis calls for careful reassessment of treatment value, clearer communication to patients and tighter scrutiny of future trials.
- Anti-amyloid drugs fall short: little benefit, safety risks (5)
- New biomarkers and imaging reshape Alzheimer’s diagnosis timing (3)
- Social and care issues: loneliness, memory and treatment decisions (2)
- All Other Stories
Anti-amyloid drugs fall short: little benefit, safety risks
New biomarkers and imaging reshape Alzheimer’s diagnosis timing
Social and care issues: loneliness, memory and treatment decisions
All Other Stories
Related Stories
The peptide problem: Hype outruns evidence, researchers caution / 2 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 7 wks
Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 2 months
Denali drug receives accelerated approval for rare CNS indication / 3 months
FDA backs three psychedelic studies with special commissioner vouchers / 2 months
FDA clears first once‑weekly basal insulin for Type 2 diabetes / 3 months
FDA approves Rocket Pharma gene therapy for ultra‑rare immune disorder / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Corporate Takeover, Obesity, Neuroscience, Supply Chain and look for the RSS link.
StackHealth Time Machine